
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : APN431
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Apeiron Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Expansion of APEIRON Biologics and Domainex Partnership will Advance Cancer Drug Discovery
Details : Domainex will provide its expertise in medicinal and computational chemistry, screening, structural biology and ADME/PK to advance APEIRON’s promising Cbl-b targeting compound series APN431 towards pre-clinical development.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 09, 2020
Lead Product(s) : APN431
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Apeiron Biologics
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Hematology
Study Phase : Discovery
Sponsor : Lunac Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Domainex inks partnership with LUNAC Therapeutics to discover novel anticoagulant therapies
Details : The partnership aims at discovering a drug that inhibits the protease target, activated Factor XII.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 25, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Hematology
Highest Development Status : Discovery
Sponsor : Lunac Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
